About Us

JOS Pharmaceuticals, a clinical stage pharmaceutical company, has pioneered the se•d8™ wafer, an orally dissolving, highly purified, natural CBD drug. Se•d8™ is for use as a prescription premedication for specific medical procedures that require an awake, conscious sedation anesthetic technique.

Purpose

Cataract surgery, LASIK and MRI imaging (performed within the tunnel enclosure machine) require a relaxed, comfortable yet awake and cooperative patient. Through research and development, the well-documented analgesic and sedative effects of cannabidiol (CBD) have been used to create a premedication to benefit both patient and physician.

The se•d8™ wafer drug delivery system is designed to allow direct absorption into the systemic circulation, bypassing both gastric and first-pass hepatic breakdown thereby enabling a more rapid and reproducible clinical response.

Any naturally occurring, residual amounts of delta-9-tetrahydrocannabinol (THC), the primary psychotomimetic chemical found in organic hemp Cannabis sativa L., have been reduced from the legal maximum of 0.3% by dry weight in certified hemp to zero (e.g. to non-detectable levels by certified GLP laboratory analysis).

New FDA Drug Approval

Our proprietary, all-natural CBD, super-lingual, drug delivery system is currently entering the NDA submission 505(b)(2) Phase 2 pathway for safety, efficacy and dose ranging clinical trials. JOS Pharmaceuticals orally dissolving CBD se•d8™ wafer uses the Zydis™ fast-dissolve lyophilized technology developed by Catalent Pharmaceutical Solutions.

Group 616
no delta 9

Reduced Delta-9 to 0%

Any naturally occurring, residual amounts of delta-9-tetrahydrocannabinol (THC), the primary psychotomimetic chemical found in organic hemp Cannabis sativa L., have been reduced from the legal maximum of 0.3% by dry weight in certified hemp to zero (e.g. to non-detectable levels by certified GLP laboratory analysis).

FDA

NDA Submission

Our proprietary, all-natural CBD, super-lingual, drug delivery system is currently entering the FDA New Drug Approval (NDA) submission 505(b)(2) Phase 2 pathway for safety, efficacy and dose ranging clinical trials. JOS Pharmaceuticals immediately, orally dissolving CBD se•d8™ wafer uses the Zydis™ fast-dissolve lyophilized technology developed by Catalent Pharmaceutical Solutions.